Chorionic Gonadotropin Injection I.P. 2000 IU ZyhCg

Chorionic Gonadotropin Injection I.P. 2000 IU ZyhCg – instructions for use

Hormonal agents are often used to eliminate pathologies, as well as to reduce the manifestations of adverse effects of steroids. Chorionic Gonadotropin Injection I.P. 2000 IU ZyhCg is one of the safest and at the same time strongest hormones.

Drug properties

The main objective of the substance is the elimination of sexual dysfunction. Gonadotropin activates testosterone production without damaging muscle volume and body contours. Bodybuilders use it to reduce the effects of strong steroids. With the artificial introduction of hormones, its natural production is significantly reduced.

The drug has positive effects:

• mimics the effect of testosterone;
• improves the function of the sex glands;
• improves spermatogenesis;
• treats infertility;
• activates puberty;
• stimulates ovulation in women;
• increases efficiency;
• reduces irritability;
• calms nervous excitement;
• improves emotional background.

Despite such qualities as a stand-alone anabolic, there is no point in using it, as it will not provide sporting results.

Dosage

Pharmacological form of Chorionic Gonadotropin Injection I.P. 2000 IU ZyhCg – powder ampoules. The container contains a concentrated solution. The liquid is drawn into the syringe and injected into a container with powder, then the agent should be mixed. There is no need for vigorous shaking. The injection is administered intramuscularly every second day.

Injections cannot be prepared more than twice, as the diluted substance loses its sterility. The finished injectable form needs to be stored in the refrigerator; the undiluted powder can be stored at room temperature.

The standard dosage is 500-3000 IU per week. A more precise rate is calculated depending on age and symptoms. The cycle lasts no more than 6 weeks.

The drug is not addictive and the body tolerates it quite easily. You do not need a prescription to buy it. But it is not recommended to use it alone. Only the treating doctor or trainer (sports doctor) can prescribe and calculate the correct hormone level.

The use stops when the steroid trace is completely eliminated from the body and a break of 10-14 days is taken. To do this, it is necessary to accurately calculate the time of activity of anabolic steroid esters in the body.

Characteristics of the course of taking

It is advisable to use gonadotropin if prolonged or combined courses of anabolic steroids have been taken.

The amount of drug and duration of use depends on the anabolic programmes completed:

• in single courses of up to 6 weeks it is not necessary to use GC;
• 8-12 week courses, combined or with high doses of steroids: hCG administration is necessary from the 5th week onwards;
• Trenbolone requires the introduction of gonadotropin in the first 4 weeks at 500-1000 IU twice a week;
• if steroids were taken for several months with hCG, then before PCT it is also necessary to break the hormone 1000-1500 IU every 4 days;
• steroid cycles for more than a year; be sure to inject all the time and before PCT at 1000-1500 IU every other day.

The half-life is several hours and the efficacy of one injection lasts 5-6 days.

Side effects and contraindications

If the dosage and recommendations are strictly followed, gonadotropin is safe for health. In case of overdose, there may be:

• swelling and fluid accumulation;
• acne;
• baldness;
• prostate enlargement;
• gynecomastia.

Chorionic Gonadotropin Injection I.P. 2000 IU ZyhCg is not recommended in the following cases:

• intolerance to the components of the composition;
• renal insufficiency;
• problems with the cardiovascular system;
• hypothyroidism;
• oncology;
• thrombophlebitis;
• lactation period;
• increased blood pressure.

Women may take the remedy only for medical reasons and only under the supervision of a doctor.

List of references

1. Fauser BCJM, Diedrich K, Devroey P. “Recombinant FSH versus urinary gonadotropins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review and meta-analysis.” Human Reproduction Update. 2007;13(5):433-440.
2. Casper RF. “Gonadotropin therapy: a 20th-century history.” Fertility and Sterility. 2012;97(4):773-778.
3. Filicori M, Cognigni GE, Taraborrelli S, et al. “Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility.” Fertility and Sterility. 2005;84(2):275-284.
4. Bosch E, Broer S, Griesinger G, et al. “Recombinant LH supplementation in women with hypo-response to controlled ovarian stimulation during IVF/ICSI: a systematic review and meta-analysis.” Human Reproduction Update. 2014;20(4):607-621.
5. European Recombinant Human Chorionic Gonadotropin Study Group. “Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction, with a combination of gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin: a prospective randomized study.” Fertility and Sterility. 2000;74(4):S38-S45.